Dr. Ann Nainan from Medicspot provides a three-step plan to help individuals manage weight regain after discontinuing weight-loss injections such as Wegovy and Mounjaro. She emphasizes the importance of gradual withdrawal and maintaining healthy habits to mitigate potential side…
As GLP-1 medications like Ozempic and Mounjaro gain popularity for managing diabetes and obesity, it's crucial to understand their nutritional implications. This article explores…
Eli Lilly's experimental obesity treatment, combining eloralintide and Mounjaro, has demonstrated an average weight loss of 23% in individuals with diabetes, highlighting its pote…
Eli Lilly's GLP-1 drug retatrutide has demonstrated remarkable efficacy in aiding individuals with Type 2 diabetes to lose up to 60 pounds, or about 23% of their body weight, acco…
A recent study indicates that tirzepatide, a treatment for obesity, may enhance metabolism by activating brown adipose tissue in obese mice. This finding could lead to new insight…
Research into GLP-1 medications, such as Ozempic and Wegovy, indicates they may play a role in reducing cancer risk by improving metabolic health, but the evidence remains mixed a…
Access to obesity drugs in the UK is divided between a slow NHS rollout of tirzepatide and a rapidly growing private market. The NHS aims to provide access over 12 years, starting…
Recent lawsuits have emerged against the makers of GLP-1 drugs like Ozempic and Wegovy, alleging insufficient warnings about a rare vision loss condition known as NAION. While stu…
Numerous lawsuits have been initiated in the United States against companies producing GLP-1 medications, such as Ozempic and Mounjaro, claiming these drugs may lead to a rare eye…
As GLP-1 medications gain popularity for weight loss, their use among college women during sorority recruitment raises concerns about body image pressures. A recent analysis indic…
As millions of individuals take GLP-1 medications like Ozempic and Wegovy, understanding how to safely fast for Yom Kippur becomes essential. While most can participate in fasting…
A recent analysis reveals that prescription rates for GLP-1 weight-loss medications, such as Wegovy and Mounjaro, are significantly lower in England's most deprived areas, despite…
NVIDIA and Eli Lilly have both reported impressive quarterly earnings, showcasing their respective growth potential. NVIDIA's revenue surged by over 105% year-over-year, driven by…
The beauty industry is rapidly evolving in response to the adoption of GLP-1 weight-loss drugs, creating a new market for beauty products that promise to counteract the side effec…
In a stunning twist of regulatory fate, the FDA has issued new hair-raising guidelines for users of GLP-1 drugs like Ozempic and Mounjaro, warning of a 37-68% increased risk of ha…